This Medudy course is a video tutorial for physicians on the topic of "New combination therapy for complicated UTIs". The format used here is a so-called "Journal Club Summary", in which we summarize the latest and most clinically relevant studies for you.
Complicated urinary tract infections, including acute pyelonephritis, cause over 600,000 hospitalizations annually in the United States and are increasingly difficult to treat due to growing resistance to β-lactam antibiotics. Taniborbactam is a novel bicyclic boronate beta-lactamase inhibitor that is active against a variety of resistant enzymes. Today's CERTAIN-1 study was conducted to evaluate the safety and efficacy of taniborbactam in combination with cefepime in hospitalized patients with complicated urinary tract infections compared to meropenem as standard therapy for resistant Gram-negative infections.
Note: All "speakers" appearing in the Medudy videos are AI-based avatars used to improve the didactics of the videos. The people on whom the avatars are based have explicitly consented to their use. All content is based on high-quality scientific sources and is created and reviewed by the Medudy medical team.
At the end of this training you will know:
- the clinical background and relevance of the research question under investigation
- Study design and methodology of the publication to answer the research question
- the results and key takeaways of the publication
- the conclusion of the publication and possible limitations
